CAMBRIDGE, Mass. (BUSINESS WIRE) FogPharma®, a biopharmaceutical company committed to transforming the lives of patients through a new precision medicine approach widely applicable to important and challenging intracellular targets, today announced the first patient has been dosed in a first-in-human Phase 1/2 cli.
LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mininggenetically-encoded small molecules (GEMs) from the biosphere, today announced the appointments of Martin Stahl
CAMBRIDGE, Mass. (BUSINESS WIRE) LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced the appointments of Martin Stahl, Ph.D., as chief scientific officer and Louis Plamondon, Ph.D., as executive.